NASDAQ:STOK
Stoke Therapeutics, Inc. Stock News
$13.90
-0.130 (-0.93%)
At Close: May 17, 2024
Stoke Therapeutics to Present at the Barclays Global Healthcare Conference
07:30am, Thursday, 04'th Mar 2021
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression w
Stoke Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
04:05pm, Monday, 04'th Jan 2021
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc., (Nasdaq: STOK), a clinical-stage biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely up
Stoke Therapeutics: A Preclinical Biopharma With A Multibillion Dollar Market Cap
03:20am, Monday, 14'th Dec 2020
Stoke Therapeutics is working in cutting edge science, however it is in early stages. It already has a very high valuation.
Stoke Therapeutics to Present at the Needham Virtual Epilepsy & Pain – Specialty CNS Therapeutics Conference
04:05pm, Friday, 04'th Dec 2020
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc., (Nasdaq: STOK), a clinical-stage biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely up
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating prote
Notable Insider Buys in the Past Week: Biglari, Coty, Danaher, Foot Locker And More
01:45pm, Saturday, 28'th Nov 2020
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying ca
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating prote
Stoke Therapeutics Announces Pricing of $97.5 Million Public Offering
07:00pm, Thursday, 19'th Nov 2020
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating prote
